Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Recombinant human thrombomodulin treatment against endotoxemia-induced myocardial injury

ABSTRACT: Recombinant human thrombomodulin treatment against endotoxemia-induced myocardial injury

PROVIDER: PRJNA543539 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Recombinant human thrombomodulin treatment against endotoxemia-induced myocardial injury

Project description:We made LPS induced myocardial injury model mice, and determined the effect of recombinant human thrombomodulin against myocardial injury.

2022-09-01 | GSE131437 | GEO

Recombinant humant thrombomodulin treatment against endotoxemia-induced acute respiratory distress syndrome (ARDS).

Project description:We made LPS induced ARDS model mice, and determined the effect of recombinant human thrombomodulin against ARDS.

2020-05-01 | GSE130362 | GEO

Recombinant humant thrombomodulin treatment against endotoxemia-induced acute respiratory distress syndrome (ARDS).

Project description:Recombinant humant thrombomodulin treatment against endotoxemia-induced acute respiratory distress syndrome (ARDS).

| PRJNA539896 | ENA

Recombinant Anti-thrombin treatment against endotoxemia-induced acute respiratory distress syndrome (ARDS).

Project description:Recombinant Anti-thrombin treatment against endotoxemia-induced acute respiratory distress syndrome (ARDS).

| PRJNA674855 | ENA

Recombinant Anti-thrombin treatment against endotoxemia-induced acute respiratory distress syndrome (ARDS).

Project description:We made LPS induced ARDS model mice, and determined the effect of recombinant anti-thrombin against ARDS.

2021-05-20 | GSE160929 | GEO

Ckmt2 for Evaluating Reperfusion Injury in Acute Myocardial Infarction

Project description:Mitochondrial Creatine Kinase 2 (Ckmt2) as a Plasma-Based Biomarker for Evaluating Reperfusion Injury in Acute Myocardial Infarction

2024-10-17 | PXD055738 | Pride

The BMAL1/HIF2A heterodimer modulates circadian variations of myocardial injury

Project description:Cardiac injury following myocardial infarction exhibits a circadian pattern, yet the underlying mechanism remains unclear. To elucidate genes governing circadian variation of myocardial injury, we conducted transcriptomic profiling of left-ventricular tissues from mice or humans experiencing myocardial injury at different daytimes. Through comprehensive analyses, including transgenic mouse models and functional studies, we identified BMAL1 as a pivotal transcription factor modulating diurnal variation of myocardial injury. Remarkably, we discovered that BMAL1 regulates circadian-dependent cardiac injury by forming a transcriptionally active heterodimer with HIF2A. Substantiating this finding, we determined the cryo-EM structure of the BMAL1/HIF2F/DNA complex, revealing a previously unknown capacity for structural rearrangement within BMAL1. Furthermore, we confirmed amphiregulin (AREG) as a transcriptional target of the BMAL1/HIF2A heterodimer, critical for modulating circadian variation of myocardial injury. Finally, targeting the BMAL1/HIF2A-AREG pathway via timed AREG administration or enhancing circadian rhythm pharmacologically offered significant cardioprotection, implicating this pathway in treating ischemic heart disease.

2024-03-20 | GSE255307 | GEO

Vitamin B12 alleviates myocardial ischemia/reperfusion injury

Project description:To examine the protective effect of B12 on myocardial ischemia/reperfusion injury and figure out the mechanism of B12.

2024-01-01 | GSE225105 | GEO

iTRAQ-MRM approach identify plasma biomarkers of atherosclerosis and myocardial injury

Project description:Current methods of stratifying patient risk of myocardial injury and stable angina rely on complex combinations of risk factors that exhibit only limited prognostic power, hence there remains a need to identify biomarkers that can be sampled non-invasively and more accurately predict patient outcomes in the clinic. In the current study, we performed comparative quantitative proteomics on whole plasma sampled from patients with stable angina (NMI), acute myocardial infarction (MI), and healthy control subjects without angina (Ctrl). We detected a total of 371 proteins with high confidence (FDR < 1%, p < 0.05), including 53 candidate biomarkers that displayed ≥ 2-fold modulated expression in patients with cardiovascular diseases (27 associated with atherosclerotic stable angina, 26 with myocardial injury). In the verification phase, we used label-free LC-MRM-MS-based targeted proteomic method to quantify and to verify the candidate biomarkers in pooled plasma, excluded peptides that were poorly distinguished from background, and then performed further validation of the remaining candidates in 49 individual plasma samples. Using this approach, we identified a final panel of 8 proteins that were both reliably and significantly modulated in disease (p < 0.05), including novel biomarkers of atherosclerotic stable angina that have been implicated in endothelial dysfunction (F10 and MST1), and previously unknown biomarkers of myocardial injury reportedly involved in either plaque destabilization (SERPINA3, CPN2, LUM) or tissue protection/repair mechanisms (ORM2, ACTG1, NAGLU). Taken together, our data showed that prognostic markers can be successfully detected in non-depleted human plasma using an iTRAQ/MRM-based discovery-validation approach, and also demonstrate that a novel panel 8 biomarkers can discriminate between the complex pathophysiologies of atherosclerotic stable angina and myocardial injury.

2018-11-06 | PXD006333 | Pride

Plasma microRNA signatures for perioperative myocardial injury.

Project description:Plasma microRNA signatures for perioperative myocardial injury.

| PRJNA604833 | ENA